The treatment of pancreatic cancer is frequently met with disappointing outcomes due to the development of resistance to therapy consequent to activation of a number of survival promoting proteins which transduce signals from extracellular signaling molecules such as epidermal growth factor (EGF), transforming growth factor (TGF), or insulin-like growth factors (IGF1) [5], [6]. This evidence concerns the gene EGF and familial pancreatic carcinoma.